Annals of Oncology 7:1015-1021, 1996
© 1996 European Society for Medical Oncology
research-article |
A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with ‘good-risk’ metastatic non-seminomatious germ cell tumors
1Department of Internal Medicine, University of Tübingen Tubingen
2Department of Urology, Städtisches Klinikum Mannheim Mannheim
3Deparment of Hematology/Oncology Klinikum Minden, Minden
4Department of Urology, Krankenhaus Am Urban Berlin
5Department of hematology/Oncology, University of Heidelberg Heidelberg
6Department of Hematology/Oncology, Hannover University Medical School Hannover
7Department of Oncology, West-German Cancer Center Essen
8Department of Hematology/Oncology, University of Halle Halle, Germany
Correspondence to: C. Bokemeyer, MD Dept. of Internal Medicine University of Tübingen Otfried-Müller-Str. 10 72076 Tübingen Germany
BACKGROUND:: Cisplatin-based combination chemotherapy will cure 70% to 80% of patients with metastatic non-seminomatous germ cell tumors but is associated with the possibility of severe neuro-, oto- and nephro-toxicities. Carboplatin, a cisplatin analogue, is an active drug in testicular cancer with a more favourable spectrum of side effects. In a randomized trial, the German Testicular Cancer Study Group compared a combination regimen of carboplatin, etoposide and bleomycin (CEB) to standard cisplatin, etoposide and bleomycin (PEB) chemotherapy for patients with ‘minimal-’ and ‘moderate-disease’ non-seminomatous germ cell tumors, according to the Indiana University classification.
PATIENTS AND METHODS:: PEB was given for three cycles at standard doses (given days 1–5), and the CEB regimen consisted of carboplatin (target AUC of 5 mg/ml x min) on day 1, etoposide 120 mg/m2 on days 1 to 3 and bleomycin 30 mg on days 1, 8 and 15. Four cycles of CEB were given, with the omission of bleomycin in the fourth cycle. Thus, the cumulative doses of etoposide and bleomycin applied in the two treatment arms were comparable. Fifty-four patients were entered on the trial, 29 were treated with PEB and 25 with CEB chemotherapy. Patients were stratified according to disease extent (minimal versus moderate) and the degree of tumor marker elevation. Thirty-two patients (59%) belonged to the group with minimal disease and low markers.
RESULTS:: No significant difference in response to chemotherapy was seen between the two arms, with CR rates of 81% for the PEB arm and 76% for CEB treatment. However, more patients treated with CEB (32% versus 13%) have relapsed after therapy, and 4 patients (16%) have died of disease progression after CEB in contrast to 1 (3%) after PEB therapy. The first interim analysis of negative events (relapse, vital tumor at secondary resection, death from the disease and therapy-associated death) showed a sigmficantly higher rate after CEB than after PEB therapy, and the trial was terminated early. After a median follow-up of 33 months for all patients, the calculation of negative events is still sigruficantly in favour of PEB-treated patients, particularly since three late relapses >2 years have been observed in the CEB arm (P = 0.03).
CONCLUSION:: This randomized trial demonstrates that even with the use of adequate doses of etoposide and full-dose bleomycin, carboplatin cannot altogether replace cisplatin in patients with testicular cancer. Treatment with the PEB regimen remains the standard approach in patients with ‘good-risk’ non-seminomatous germ cell tumors.
carboplatin, chemotherapy, cisplatin, Indiana University classification, prognostic factors, randomized study, testicular cancer, toxicity
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Laskin, A. Sandler, and D. H. Johnson An Advance in Small-Cell Lung Cancer Treatment--More or Less J Natl Cancer Inst, August 6, 2003; 95(15): 1099 - 1101. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mueller, W. Voigt, H. Simon, A. Fruehauf, A. Bulankin, A. Grothey, and H.-J. Schmoll Failure of Activation of Caspase-9 Induces a Higher Threshold for Apoptosis and Cisplatin Resistance in Testicular Cancer Cancer Res., January 15, 2003; 63(2): 513 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-C. Soria and T. Le Chevalier Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann. Onc., October 1, 2002; 13(10): 1515 - 1517. [Full Text] [PDF]
|
|
|
|
|
|
K. Fizazi, K.-A. Do, X. Wang, L. Finn, C. J. Logothetis, and R. J. Amato A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial Ann. Onc., January 19, 2002; 13(1): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Mann, F. Raafat, K. Robinson, J. Imeson, P. Gornall, M. Sokal, E. Gray, P. McKeever, J. Hale, S. Bailey, et al. The United Kingdom Children's Cancer Study Group's Second Germ Cell Tumor Study: Carboplatin, Etoposide, and Bleomycin Are Effective Treatment for Children With Malignant Extracranial Germ Cell Tumors, With Acceptable Toxicity J. Clin. Oncol., November 15, 2000; 18(22): 3809 - 3818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Go and A. A. Adjei Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin J. Clin. Oncol., January 1, 1999; 17(1): 409 - 409. [Abstract] [Full Text] [PDF]
|
|